Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLPE.L Regulatory News (SLPE)

  • There is currently no data for SLPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Quarterly Investment Update at 30 June 2020

30 Sep 2020 07:00

RNS Number : 4793A
Standard Life Private Eqty Trst PLC
30 September 2020
 

Standard Life Private Equity Trust plc

Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13

 

1. Investment update for the quarter ended 30 June 2020

 

· The net asset value ("NAV") per ordinary share of Standard Life Private Equity Trust plc ("the Company") increased by 11.1% to 473.9 pence for the quarter ended 30 June 2020

· Realised gains and income on the portfolio during the quarter ended 30 June 2020 totalled £18.2 million (2.8% of NAV). The unrealised gain on a constant exchange rate basis was £46.3 million (7.1% of NAV). In addition, there were unrealised foreign exchange gains of £14.8 million (2.2% of NAV)

· The first interim dividend for the financial year ending 30 September 2020 of 3.3 pence per share was paid on 24 April 2020

· 100.0% by value of the portfolio was valued by the respective underlying managers at 30 June 2020

· NAV total return was 11.9% for the three months from 1 April 2020 to 30 June 2020

· Outstanding commitments were £465.5 million at 30 June 2020

· Cash and cash equivalents were £52.0 million at 30 June 2020

 

For the quarter ended 30 June 2020, the Company's NAV increased by 11.1% to 473.9 pence per share from 426.4 pence per share at 31 March 2020. At 30 June 2020, the Company's net assets were £728.6 million (31 March 2020 - £655.6 million). NAV total return was 11.9% for the three months from 1 April 2020 to 30 June 2020.

 

The closing value of the Company's portfolio, which included 63 private equity interests, was £660.9 million at 30 June 2020 (31 March 2020 - £580.3 million and 62 private equity interests). 100.0% by value of the portfolio valuations were dated 30 June 2020. The valuations by the underlying managers as at 30 June 2020 have not been adjusted by the Manager.

 

The total unrealised gain on the portfolio for the quarter ended 30 June 2020 was £61.1 million (9.3%), comprising £46.3 million (7.1%) of unrealised gain on a constant exchange rate basis and £14.8 million (2.2%) of unrealised foreign exchange gains. The capital movement of the FTSE All-Share Index (in sterling) was + 9.8% during the quarter. The unrealised foreign exchange gains were driven by the Euro and the US Dollar appreciating by 2.7% and 0.4% respectively relative to sterling over the quarter.

 

During the quarter ended 30 June 2020, the portfolio generated £30.0 million of distributions (quarter ended 31 March 2020 - £64.6 million). The Company funded £31.2 million of drawdowns (quarter ended 31 March 2020 - £44.0 million) into the portfolio. The portfolio distributions received during the quarter generated £18.2 million (2.8%) of net realised gains and income. This was equivalent to a return of 2.5 times the acquisition cost of the realised investments.

 

The Company made a new primary commitment during the quarter of €25.0 million to Vitruvian IV. The Company had total outstanding commitments to its 63 private equity interests of £465.5 million at 30 June 2020 (31 March 2020 - £451.2 million to 62 private equity interests). The Manager believes that around £68.3 million of the Company's outstanding commitments at 30 June 2020 are unlikely to be drawn.

 

The Company had cash and cash equivalents of £52.0 million at 30 June 2020 (31 March 2020 - £59.6 million). In addition, it is due £15.5 million (31 March 2020 - £15.2 million) of deferred consideration during the year from investments sold in 2019. The Company also had an undrawn £100.0 million syndicated revolving credit facility provided by Citi and Societe Generale, expiring in December 2024.

 

 

2. Activity since 30 June 2020

 

On 31 July 2020, the Company paid the second interim dividend for the year ending 30 September 2020 of 3.3 pence per ordinary share. The cost of the dividend was £4.9 million. In addition, the Company declared a third quarter dividend for the year ending 30 September 2020 of 3.3 pence per ordinary share, to be paid on 30 October, to shareholders on the Company's share register as at 25 September 2020.

 

During the period from 1 July 2020 to 14 September 2020 the Company received £16.4 million of distributions and funded £18.4 million of drawdowns and co-investment funding.

 

In August 2020, the Company made a $7.0 million co-investment into Visma, a leading provider of mission critical enterprise resource planning software in the Nordics and the Netherlands. The co-investment was made alongside Hg, Visma's lead investor.

 

The Company had cash and cash equivalents of £43.1 million at 14 September 2020. In addition, it is due £15.5 million of deferred consideration during the year from investments sold in 2019. The Company also had total outstanding commitments of £440.1 million. The Manager believes that around £66.3 million of the Company's outstanding commitments are unlikely to be drawn.

 

In September 2020, the syndicated revolving credit facility was expanded to £200.0 million from £100.0 million. This expansion of the existing facility includes the introduction of State Street Bank International as a new lender to the Company alongside long-term lenders Citi and Societe Generale. The expiry date of the facility remains as December 2024.

 

 

3. Update on COVID-19

 

The Manager continues to be mindful of the impact of COVID-19 and maintains regular communication with the private equity managers of the Company's investments. Whilst the Company's NAV has recovered strongly this quarter following a decline of 8.2% in Company NAV in March, the Manager remains cautious in respect of the valuation of the Company's portfolio in the coming quarters.

 

An update from the Manager, which provides responses to frequently asked questions in relation to COVID-19, is available within the Latest News section of the Company website; www.slpet.co.uk.

 

 

4. Future Announcements

 

The Company's estimated NAV at 31 August 2020 is also being announced today. The Company is expecting to announce its estimated NAV at 30 September 2020 on 14 October 2020.

 

It is anticipated that the Company will release its results for the year ending 30 September 2020 on or around 25 January 2021.

 

For further information please contact:-

 

Alan Gauld at SL Capital Partners LLP (0131 528 4424)

 

Note:-

Standard Life Private Equity Trust PLC is an investment company managed by SL Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under sections 1158-1165 of the Corporation Tax Act 2010. The Board of Standard Life Private Equity Trust PLC is independent of Standard Life Aberdeen plc and Phoenix Group Holdings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUKASRRUUKUAR
Date   Source Headline
7th Dec 20124:53 pmRNSTransaction in Own Shares
3rd Dec 20127:00 amRNSPreliminary Results
1st Oct 201210:48 amRNSQuarterly Disclosure
19th Sep 20127:00 amRNSQuarterly Trading Statement
17th Aug 201210:57 amRNSInterim Management Statement
9th Jul 20125:04 pmRNSHolding(s) in Company
9th Jul 201211:44 amRNSHolding(s) in Company
2nd Jul 20122:39 pmRNSQuarterly Disclosure
1st Jun 20124:56 pmRNSDirector/PDMR Shareholding
29th May 20125:28 pmRNSHalf Yearly Report
24th May 20129:10 amRNSDirector Declaration
2nd Apr 201212:43 pmRNSQuarterly Disclosure
21st Mar 20127:00 amRNSQuarterly Trading Statement
1st Mar 20129:47 amRNSTotal Voting Rights
24th Feb 20129:09 amRNSHolding(s) in Company
22nd Feb 20127:30 amRNSCompany Secretary Change
14th Feb 20122:18 pmRNSDirector/PDMR Shareholding
6th Feb 20124:16 pmRNSDirector/PDMR Shareholding
6th Feb 20124:16 pmRNSDirector/PDMR Shareholding
6th Feb 20124:15 pmRNSDirector/PDMR Shareholding
2nd Feb 20124:45 pmRNSInterim Management Statement
2nd Feb 20124:40 pmRNSSecretary Change
2nd Feb 20124:35 pmRNSResult of AGM
2nd Feb 20124:27 pmRNSDirectorate Change
1st Feb 20129:21 amRNSIssue of Equity
30th Jan 201211:24 amRNSAnnual Financial Report
12th Jan 20124:46 pmRNSAnnual Information Update
11th Jan 20123:32 pmRNSScrip dividend reference price
5th Jan 201210:56 amRNSQuarterly Disclosure
16th Dec 201111:15 amRNSDoc re. Annual Report & Circular
12th Dec 201110:26 amRNSDirector/PDMR Shareholding
7th Dec 20113:42 pmRNSDirector/PDMR Shareholding
5th Dec 20114:19 pmRNSDirector/PDMR Shareholding
5th Dec 20112:20 pmRNSDirector/PDMR Shareholding
5th Dec 20117:00 amRNSPreliminary Results
29th Nov 20113:55 pmRNSHolding(s) in Company
11th Oct 201110:22 amRNSDirector Declaration
5th Oct 20117:00 amRNSManagement Incentive Scheme Arrangements
4th Oct 20114:17 pmRNSQuarterly Disclosure
21st Sep 20117:00 amRNSQuarterly Trading Statement
11th Aug 20117:00 amRNSInterim Management Statement
20th Jul 201110:48 amRNSHolding(s) in Company
4th Jul 20111:08 pmRNSQuarterly Disclosure
15th Jun 201110:31 amRNSDirector/PDMR Shareholding
14th Jun 20113:46 pmRNSDirector/PDMR Shareholding
2nd Jun 20119:26 amRNSReplacement - Half Yearly Report
27th May 20117:00 amRNSHalf Yearly Report
4th Apr 20112:57 pmRNSQuarterly Disclosure
1st Apr 20117:00 amRNSDirectorate Change
21st Mar 20113:09 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.